看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
4 k z8 a6 f7 F+ W
A5 E% s5 W2 C6 s5 w8 R' @3 K0 K, Q
' ^# \2 B2 l! ^# A+ U- _Currently available feasibility data for possible combination strategies. . j( \1 D( Y! F7 V7 T3 j v
————————————————————————————————
& C3 F3 ]! r' t* ^' o& ^Combination Feasibility according to preliminary data
: `, I4 X; z. |. e——————————————————————————————————
6 ~+ L: m, m4 C- ^$ k1 K- K( cBevacizumab + sorafenib Yes, reduced dose
/ L4 D# e0 z( kBevacizumab + sunitinib† No ; ^* \& V, F z `: O! x
Bevacizumab + temsirolimus Yes
O, k5 B9 s2 f3 M4 Y' MBevacizumab + everolimus Yes * c! G* l ^6 F' F: G/ a
Sorafenib + sunitinib ? 9 m7 z4 [ {# d: J/ h
Sorafenib + temsirolimus Yes, reduced dose ' o- {1 E6 A; J% y+ X7 G
Sorafenib + everolimus Yes, reduced dose
" D. Y; T& r+ {9 {! {Sunitinib + temsirolimus† No
+ B; A. }* k: C7 {2 C$ T7 j; GSunitinib + everolimus ? 2 ^, V" P7 L7 M, L& \2 S; X' a6 Z
Temsirolimus + everolimus ?
7 ^% B0 \5 l$ X- d————————————————————
, }8 E6 w9 n$ b†Led to US FDA warning.0 Y" L2 a( m. t; l. k* \4 g
?: As yet unattempted combination.
' C0 Z% A8 r+ h* \1 I a |